LFCR · Lifecore Biomedical, Inc. \De\
$6.53
-0.05 (-0.76%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$158.98M
Shares
37.85M
Volume · Oct 1
707.1K
Avg daily vol (3M)
232.17K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.53
Open$6.57
Day$6.53–6.58
52W close$3.66–8.82
Avg vol 30d337K
Short int2.7M · 7.1% float · 15.9d
Short vol20%
Last earningsAug 5, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 5 wks
filed Aug 5, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+0.5%
Year over year
Operating margin
-13.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-5.0%
Year over year · fewer shares
Price change (1Y)
-8.9%
Trailing year
Short interest
7.1%
Latest settlement · 15.9 days to cover
AI Brief
Q1 FY26 earnings call · May 6, 2026
Q1 FY26
TL;DR. LifeCore reported Q1 2026 revenue of $23.2 million, down 34% year-over-year, with a net loss of $15.0 million and adjusted EBITDA of $1.0 million, while reaffirming full-year 2026 guidance and signing three new commercial site transfer programs expected to contribute revenue in 2028.
Bullish
- + Reaffirmed full-year 2026 guidance for revenue of $120-$125 million and adjusted EBITDA of $20.5-$25 million
- + Signed three new commercial site transfer programs in Q1 2026, expected to generate mid-seven-figure revenue opportunities starting in 2028 new
- + Recorded sixth consecutive quarter of period-over-period declines in SG&A and R&D, with cumulative reductions of almost $8 million since late 2024 new
- + Generated $4.7 million in cash from operations and $3.6 million in free cash flow, marking the fifth consecutive quarter of positive operating cash flow new
- + Ended Q1 2026 with approximately $38.1 million in liquidity, including $20.8 million in cash and $17.3 million of revolver availability new
Bearish
- − Q1 2026 revenue declined 34% to $23.2 million from $35.2 million year-over-year, a decrease of $12.0 million new
- − Gross profit margin compressed to 19% from 28% in the prior-year quarter, with gross profit falling $5.4 million to $4.5 million new
- − Adjusted EBITDA declined $4.7 million to $1.0 million from $5.7 million in the prior-year quarter new
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Mentioned in fund letters
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+15%
above
Price vs 50-day avg
+41%
above
RSI (14)
78
overbought
MACD trend
Positive
52-week position
56%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+38%
trailing
6-month return
+37%
trailing
YTD return
−20%
this year
Relative strength
+25%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.05% of float · ▲ +10.2% MoM · 15.9 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
100 holders — mid 3-yr range
Squeeze score
100
high risk · 0–100
Fundamentals
Revenue growth
+6%
Y/Y
Gross margin
7%
contracting
EPS growth
−485%
Y/Y
Free cash flow
$-13.6M
Buyback
$3.8M
authorized
Balance sheet
$122.2M
net debt
Quant / Vol
risk profile
Volatility
81%
annualized · 1-yr
Max drawdown
−59%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Revenue
· fiscal year 2029
Initiated
$212M – $225M
Adjusted EBITDA margin
· fiscal year 2029
Non-GAAP
Initiated
at least 25%
Prior guidance
period ended
· from the Earnings Call filed May 6, 2026
Total revenue
· 2026
$120M – $125M
Adjusted EBITDA
· 2026
$20.5M – $25M
Guided vs delivered
· last 1 settled
Revenue
full year fiscal 2024
guided $125M – $130M
$128.26M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+15%
Bullish
Price vs 50-day avg
+41%
Bullish
RSI (14)
78
Bearish
MACD trend
Positive
Bullish
52-week position
56%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.05% of float · ▲ +10.2% MoM · 15.9 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
100 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4
Now $7 · 56%
Range high $9
vs 200-day avg +15%
vs 50-day avg +41%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LFCR
this stock
Lifecore Biomedical, Inc. \De\
|
$158.98M | -20.2% | +6.4% | — | 7.1% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.0% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.7% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LFCR | +52.2% | +37.8% | +37.5% | -0.8% | -20.2% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | +52.6% | +37.9% | +25.0% | -0.9% | -32.2% |
Capital returns
Buyback program
· as of Feb 26, 2023
Authorized
$3.80M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.